Explore

Trendline Trendline
Molecular Targeting Technologies Unveils Promising Data for GEP-NET Cancer Treatment

Molecular Targeting Technologies Unveils Promising Data for GEP-NET Cancer Treatment

Molecular Targeting Technologies Unveils Promising Data for GEP-NET Cancer Treatment
Trendline Trendline
FDA Approves AbbVie's Decnupaz for Ultra-Rare Blood Cancer Treatment

FDA Approves AbbVie's Decnupaz for Ultra-Rare Blood Cancer Treatment

FDA Approves AbbVie's Decnupaz for Ultra-Rare Blood Cancer Treatment
Trendline Trendline
Ori Biotech and ImmuXell Partner to Advance TCR-T Cell Therapy for Cancer Treatment

Ori Biotech and ImmuXell Partner to Advance TCR-T Cell Therapy for Cancer Treatment

Ori Biotech and ImmuXell Partner to Advance TCR-T Cell Therapy for Cancer Treatment
Trendline Trendline
Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones

Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones

Ernexa Therapeutics Advances ERNA-101 Toward Clinical Trials with Key Milestones
Trendline Trendline
Ori Biotech and ImmuXell Partner to Advance Cell Therapy Manufacturing

Ori Biotech and ImmuXell Partner to Advance Cell Therapy Manufacturing

Ori Biotech and ImmuXell Partner to Advance Cell Therapy Manufacturing
Trendline Trendline
Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors

Forlong Biotechnology Completes Phase I Trials of FL115 for Advanced Tumors
Trendline Trendline
Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors
Trendline Trendline
Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics to Present Novel IL-12 Anchored Immunotherapy at ASCO 2026
Trendline Trendline
Biopharma Companies Explore PD-(L)1×VEGF Bispecifics Beyond Lung Cancer

Biopharma Companies Explore PD-(L)1×VEGF Bispecifics Beyond Lung Cancer

Biopharma Companies Explore PD-(L)1×VEGF Bispecifics Beyond Lung Cancer
Trendline Trendline
Ankyra Therapeutics Presents Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics Presents Novel IL-12 Anchored Immunotherapy at ASCO 2026

Ankyra Therapeutics Presents Novel IL-12 Anchored Immunotherapy at ASCO 2026
Trendline Trendline
Coya Therapeutics to Present ALS Trial Design at Upcoming Summit

Coya Therapeutics to Present ALS Trial Design at Upcoming Summit

Coya Therapeutics to Present ALS Trial Design at Upcoming Summit
Trendline Trendline
Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment

Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment

Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment